# OnCo record nct05584670 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05584670/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05584670", "NCT05584670" ;
  schema:name "A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab in advanced solid tumours, run by Sanofi, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05584670/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05584670> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-11-29" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/adg126/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/sanofi/> .